 George Wang
Concepts (296)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cannabis | 29 | 2025 | 518 | 6.640 |
Why?
| | Poison Control Centers | 12 | 2022 | 85 | 4.390 |
Why?
| | Drug Overdose | 10 | 2026 | 381 | 3.710 |
Why?
| | Legislation, Drug | 7 | 2021 | 73 | 2.710 |
Why?
| | Medical Marijuana | 5 | 2022 | 122 | 2.540 |
Why?
| | Marijuana Use | 6 | 2026 | 222 | 2.360 |
Why?
| | Hallucinogens | 6 | 2024 | 112 | 2.340 |
Why?
| | Analgesics, Opioid | 9 | 2026 | 1167 | 2.320 |
Why?
| | Dronabinol | 13 | 2025 | 251 | 2.160 |
Why?
| | Marijuana Smoking | 9 | 2024 | 249 | 2.110 |
Why?
| | Marijuana Abuse | 5 | 2024 | 215 | 2.050 |
Why?
| | Poisoning | 8 | 2025 | 119 | 1.870 |
Why?
| | Hospitals, Pediatric | 9 | 2022 | 571 | 1.630 |
Why?
| | Cannabinoids | 6 | 2023 | 184 | 1.610 |
Why?
| | Emergency Service, Hospital | 15 | 2021 | 2416 | 1.600 |
Why?
| | Fentanyl | 3 | 2026 | 128 | 1.590 |
Why?
| | Nonprescription Drugs | 4 | 2022 | 69 | 1.550 |
Why?
| | Drug Packaging | 3 | 2018 | 41 | 1.530 |
Why?
| | Diphenhydramine | 6 | 2022 | 36 | 1.460 |
Why?
| | Poisons | 2 | 2022 | 20 | 1.410 |
Why?
| | Hypotension | 4 | 2022 | 127 | 1.330 |
Why?
| | Cough | 3 | 2022 | 124 | 1.320 |
Why?
| | Vomiting | 3 | 2021 | 131 | 1.280 |
Why?
| | Substance Abuse Detection | 6 | 2025 | 112 | 1.260 |
Why?
| | Eating | 7 | 2023 | 387 | 1.240 |
Why?
| | Child | 39 | 2026 | 22980 | 1.150 |
Why?
| | Substance-Related Disorders | 4 | 2019 | 1112 | 1.130 |
Why?
| | Child, Preschool | 27 | 2026 | 12017 | 1.070 |
Why?
| | Prescription Drugs | 2 | 2020 | 111 | 1.000 |
Why?
| | Humans | 88 | 2026 | 147306 | 0.970 |
Why?
| | Epilepsy | 3 | 2020 | 399 | 0.960 |
Why?
| | Infant | 24 | 2026 | 10195 | 0.960 |
Why?
| | Antitussive Agents | 3 | 2021 | 7 | 0.950 |
Why?
| | Analgesics, Non-Narcotic | 2 | 2022 | 131 | 0.940 |
Why?
| | Medication Errors | 2 | 2019 | 85 | 0.930 |
Why?
| | Colorado | 16 | 2023 | 4591 | 0.890 |
Why?
| | Adolescent | 30 | 2025 | 22826 | 0.850 |
Why?
| | Muscarinic Antagonists | 2 | 2022 | 30 | 0.830 |
Why?
| | Dextromethorphan | 3 | 2021 | 24 | 0.800 |
Why?
| | Eyelids | 1 | 2024 | 41 | 0.800 |
Why?
| | Oxycodone | 2 | 2021 | 52 | 0.800 |
Why?
| | Multi-Ingredient Cold, Flu, and Allergy Medications | 2 | 2020 | 3 | 0.780 |
Why?
| | Phytotherapy | 2 | 2013 | 74 | 0.740 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 3 | 2022 | 267 | 0.740 |
Why?
| | Psychotropic Drugs | 2 | 2021 | 79 | 0.720 |
Why?
| | Retrospective Studies | 21 | 2026 | 17561 | 0.710 |
Why?
| | Ambulatory Care | 4 | 2021 | 625 | 0.710 |
Why?
| | Fractures, Closed | 1 | 2022 | 16 | 0.710 |
Why?
| | Prescription Drug Monitoring Programs | 1 | 2022 | 17 | 0.710 |
Why?
| | Female | 46 | 2026 | 80081 | 0.690 |
Why?
| | Cannabidiol | 2 | 2022 | 142 | 0.680 |
Why?
| | Hyperthermia, Induced | 1 | 2022 | 120 | 0.670 |
Why?
| | Bupropion | 1 | 2021 | 48 | 0.660 |
Why?
| | Akathisia, Drug-Induced | 1 | 2020 | 5 | 0.660 |
Why?
| | Physostigmine | 1 | 2020 | 13 | 0.660 |
Why?
| | Narcotic Antagonists | 2 | 2026 | 210 | 0.660 |
Why?
| | Lorazepam | 1 | 2020 | 26 | 0.650 |
Why?
| | Acute Pain | 1 | 2021 | 58 | 0.640 |
Why?
| | United States | 18 | 2025 | 16313 | 0.640 |
Why?
| | Male | 39 | 2026 | 73954 | 0.630 |
Why?
| | Arrhythmias, Cardiac | 2 | 2022 | 360 | 0.620 |
Why?
| | Clenbuterol | 1 | 2019 | 3 | 0.610 |
Why?
| | Anesthesia | 1 | 2023 | 257 | 0.600 |
Why?
| | Black Widow Spider | 1 | 2019 | 7 | 0.600 |
Why?
| | Spider Venoms | 1 | 2019 | 11 | 0.600 |
Why?
| | Common Cold | 1 | 2019 | 16 | 0.600 |
Why?
| | Psychotic Disorders | 1 | 2022 | 199 | 0.590 |
Why?
| | Delirium | 1 | 2020 | 106 | 0.580 |
Why?
| | Designer Drugs | 1 | 2019 | 7 | 0.580 |
Why?
| | Bradycardia | 2 | 2023 | 63 | 0.570 |
Why?
| | Biguanides | 1 | 2018 | 10 | 0.560 |
Why?
| | Plant Extracts | 1 | 2020 | 191 | 0.550 |
Why?
| | Buprenorphine, Naloxone Drug Combination | 1 | 2018 | 13 | 0.540 |
Why?
| | Face | 1 | 2019 | 176 | 0.530 |
Why?
| | Mass Spectrometry | 1 | 2021 | 728 | 0.530 |
Why?
| | Capsaicin | 1 | 2017 | 30 | 0.530 |
Why?
| | Schizophrenia | 1 | 2022 | 489 | 0.520 |
Why?
| | Anticonvulsants | 1 | 2020 | 253 | 0.520 |
Why?
| | Child Abuse | 2 | 2022 | 558 | 0.520 |
Why?
| | Tertiary Care Centers | 2 | 2017 | 196 | 0.510 |
Why?
| | Accidents, Home | 1 | 2017 | 33 | 0.510 |
Why?
| | Antiemetics | 1 | 2017 | 51 | 0.510 |
Why?
| | Tachycardia | 2 | 2019 | 58 | 0.510 |
Why?
| | Drug Storage | 1 | 2017 | 53 | 0.500 |
Why?
| | Emergency Services, Psychiatric | 1 | 2017 | 31 | 0.490 |
Why?
| | Acetaminophen | 3 | 2022 | 269 | 0.490 |
Why?
| | Acetylcysteine | 2 | 2022 | 139 | 0.480 |
Why?
| | Drug and Narcotic Control | 1 | 2016 | 24 | 0.480 |
Why?
| | Renal Insufficiency | 1 | 2018 | 172 | 0.470 |
Why?
| | Emergency Medicine | 1 | 2019 | 283 | 0.470 |
Why?
| | Fractures, Bone | 1 | 2021 | 433 | 0.470 |
Why?
| | Buprenorphine | 1 | 2020 | 201 | 0.470 |
Why?
| | Hyperammonemia | 1 | 2015 | 17 | 0.450 |
Why?
| | Food | 1 | 2016 | 150 | 0.440 |
Why?
| | Methanol | 1 | 2015 | 44 | 0.440 |
Why?
| | Tobacco Smoke Pollution | 2 | 2021 | 227 | 0.430 |
Why?
| | Metformin | 1 | 2018 | 329 | 0.420 |
Why?
| | Seizures | 1 | 2019 | 491 | 0.420 |
Why?
| | Toxicology | 1 | 2015 | 49 | 0.420 |
Why?
| | Electrocardiography | 2 | 2019 | 675 | 0.410 |
Why?
| | Hospitalization | 3 | 2022 | 2496 | 0.400 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 28 | 0.390 |
Why?
| | Plant Preparations | 1 | 2013 | 37 | 0.380 |
Why?
| | Drug Monitoring | 1 | 2017 | 402 | 0.380 |
Why?
| | Students | 1 | 2019 | 659 | 0.380 |
Why?
| | Plasmapheresis | 1 | 2013 | 24 | 0.380 |
Why?
| | Accidents | 1 | 2013 | 46 | 0.380 |
Why?
| | Amphotericin B | 1 | 2013 | 36 | 0.380 |
Why?
| | Ethers | 1 | 2012 | 19 | 0.370 |
Why?
| | Risk Assessment | 3 | 2017 | 3784 | 0.370 |
Why?
| | Flecainide | 1 | 2012 | 8 | 0.370 |
Why?
| | Asymptomatic Diseases | 1 | 2013 | 104 | 0.370 |
Why?
| | Antifungal Agents | 1 | 2013 | 153 | 0.350 |
Why?
| | Pharmacy | 1 | 2012 | 32 | 0.350 |
Why?
| | Adult | 15 | 2026 | 41406 | 0.350 |
Why?
| | Acid-Base Equilibrium | 2 | 2022 | 23 | 0.350 |
Why?
| | Drug Compounding | 1 | 2012 | 107 | 0.340 |
Why?
| | Tremor | 2 | 2024 | 98 | 0.330 |
Why?
| | Cholinergic Antagonists | 1 | 2011 | 24 | 0.330 |
Why?
| | Free Radical Scavengers | 1 | 2011 | 82 | 0.330 |
Why?
| | Hospital Rapid Response Team | 1 | 2010 | 20 | 0.320 |
Why?
| | Cannabinoid Receptor Agonists | 4 | 2023 | 44 | 0.320 |
Why?
| | Liver Failure | 1 | 2011 | 83 | 0.310 |
Why?
| | Health Facilities | 2 | 2022 | 85 | 0.310 |
Why?
| | Antivenins | 2 | 2020 | 29 | 0.310 |
Why?
| | Antidotes | 2 | 2022 | 145 | 0.310 |
Why?
| | Population Surveillance | 1 | 2013 | 486 | 0.310 |
Why?
| | Referral and Consultation | 2 | 2021 | 886 | 0.300 |
Why?
| | Practice Patterns, Physicians' | 4 | 2023 | 1379 | 0.300 |
Why?
| | Patient Acceptance of Health Care | 3 | 2022 | 895 | 0.290 |
Why?
| | Tandem Mass Spectrometry | 4 | 2025 | 575 | 0.280 |
Why?
| | Acidosis | 2 | 2021 | 107 | 0.280 |
Why?
| | Hypoglycemic Agents | 1 | 2018 | 1415 | 0.280 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 649 | 0.260 |
Why?
| | Pediatrics | 2 | 2017 | 1139 | 0.260 |
Why?
| | Suicide, Attempted | 1 | 2011 | 430 | 0.250 |
Why?
| | Incidence | 3 | 2021 | 2954 | 0.240 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2025 | 394 | 0.230 |
Why?
| | Appetite | 1 | 2026 | 80 | 0.230 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 115 | 0.230 |
Why?
| | Half-Life | 2 | 2019 | 157 | 0.230 |
Why?
| | Young Adult | 7 | 2024 | 14437 | 0.220 |
Why?
| | Public Health | 4 | 2025 | 577 | 0.210 |
Why?
| | Naloxone | 1 | 2026 | 138 | 0.210 |
Why?
| | Cross-Sectional Studies | 4 | 2021 | 6011 | 0.210 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2018 | 2627 | 0.200 |
Why?
| | Analgesics | 2 | 2023 | 231 | 0.200 |
Why?
| | Shock | 1 | 2025 | 110 | 0.200 |
Why?
| | Intensive Care Units, Pediatric | 2 | 2019 | 294 | 0.190 |
Why?
| | Infant, Newborn | 4 | 2025 | 6543 | 0.190 |
Why?
| | Hemodiafiltration | 1 | 2022 | 7 | 0.180 |
Why?
| | Research Design | 2 | 2025 | 1158 | 0.180 |
Why?
| | Case-Control Studies | 2 | 2022 | 3660 | 0.180 |
Why?
| | Prescriptions | 1 | 2021 | 75 | 0.170 |
Why?
| | Infusions, Intravenous | 2 | 2013 | 430 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2024 | 2030 | 0.160 |
Why?
| | Prevalence | 2 | 2019 | 2889 | 0.160 |
Why?
| | Snake Bites | 1 | 2020 | 24 | 0.160 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2020 | 56 | 0.160 |
Why?
| | Anti-Anxiety Agents | 1 | 2020 | 48 | 0.160 |
Why?
| | Syndrome | 1 | 2021 | 385 | 0.160 |
Why?
| | Feeding Behavior | 1 | 2026 | 693 | 0.160 |
Why?
| | Databases, Factual | 3 | 2021 | 1504 | 0.160 |
Why?
| | Hospitals | 2 | 2023 | 740 | 0.160 |
Why?
| | Length of Stay | 3 | 2021 | 1371 | 0.160 |
Why?
| | Heart Rate | 1 | 2024 | 860 | 0.160 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2023 | 339 | 0.150 |
Why?
| | Drug Prescriptions | 1 | 2022 | 293 | 0.150 |
Why?
| | Flank Pain | 1 | 2019 | 9 | 0.150 |
Why?
| | Performance-Enhancing Substances | 1 | 2019 | 11 | 0.150 |
Why?
| | Poisson Distribution | 1 | 2019 | 78 | 0.150 |
Why?
| | Public Health Surveillance | 1 | 2019 | 83 | 0.150 |
Why?
| | Adrenergic beta-Agonists | 1 | 2019 | 92 | 0.150 |
Why?
| | Heart Arrest | 1 | 2023 | 412 | 0.150 |
Why?
| | Temperature | 1 | 2022 | 638 | 0.140 |
Why?
| | Milk, Human | 1 | 2021 | 176 | 0.140 |
Why?
| | Cardiotoxicity | 1 | 2019 | 35 | 0.140 |
Why?
| | Biological Availability | 1 | 2019 | 146 | 0.140 |
Why?
| | Sodium Bicarbonate | 1 | 2019 | 48 | 0.140 |
Why?
| | Morphine | 1 | 2020 | 169 | 0.140 |
Why?
| | Self Report | 2 | 2024 | 887 | 0.140 |
Why?
| | Hyperlactatemia | 1 | 2018 | 3 | 0.140 |
Why?
| | Epidemics | 1 | 2020 | 96 | 0.140 |
Why?
| | Drug Utilization | 1 | 2019 | 171 | 0.140 |
Why?
| | Tissue Distribution | 1 | 2019 | 335 | 0.140 |
Why?
| | Reproducibility of Results | 2 | 2024 | 3448 | 0.140 |
Why?
| | Adolescent Health | 1 | 2018 | 38 | 0.140 |
Why?
| | Methadone | 1 | 2020 | 131 | 0.140 |
Why?
| | Treatment Outcome | 4 | 2020 | 11947 | 0.130 |
Why?
| | Vulnerable Populations | 1 | 2019 | 177 | 0.130 |
Why?
| | Prospective Studies | 3 | 2021 | 8166 | 0.130 |
Why?
| | Administration, Topical | 1 | 2017 | 156 | 0.130 |
Why?
| | Urine | 1 | 2017 | 64 | 0.130 |
Why?
| | Physical Examination | 1 | 2018 | 245 | 0.120 |
Why?
| | Health Surveys | 1 | 2019 | 522 | 0.120 |
Why?
| | Respiratory Tract Infections | 1 | 2021 | 399 | 0.120 |
Why?
| | Regression Analysis | 1 | 2019 | 1003 | 0.120 |
Why?
| | Risk Factors | 4 | 2017 | 11017 | 0.120 |
Why?
| | Preventive Health Services | 1 | 2018 | 154 | 0.120 |
Why?
| | Administration, Oral | 1 | 2019 | 874 | 0.120 |
Why?
| | Physician's Role | 1 | 2018 | 225 | 0.120 |
Why?
| | Universities | 1 | 2019 | 453 | 0.120 |
Why?
| | Pregnancy | 2 | 2022 | 7276 | 0.120 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 528 | 0.120 |
Why?
| | Plasma | 1 | 2017 | 224 | 0.110 |
Why?
| | Double-Blind Method | 1 | 2020 | 2080 | 0.110 |
Why?
| | Pain Management | 1 | 2019 | 415 | 0.110 |
Why?
| | Tea Tree Oil | 1 | 2015 | 2 | 0.110 |
Why?
| | Child Behavior | 1 | 2017 | 238 | 0.110 |
Why?
| | Fatal Outcome | 1 | 2015 | 306 | 0.100 |
Why?
| | Renal Replacement Therapy | 1 | 2015 | 104 | 0.100 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 99 | 0.100 |
Why?
| | Odds Ratio | 1 | 2017 | 1084 | 0.100 |
Why?
| | Glasgow Coma Scale | 1 | 2015 | 218 | 0.100 |
Why?
| | Pulmonary Surfactants | 1 | 2015 | 105 | 0.100 |
Why?
| | Middle Aged | 5 | 2024 | 36821 | 0.100 |
Why?
| | Parents | 2 | 2021 | 1428 | 0.100 |
Why?
| | Guanfacine | 1 | 2013 | 5 | 0.100 |
Why?
| | Clonidine | 1 | 2013 | 33 | 0.100 |
Why?
| | Pandemics | 1 | 2022 | 1720 | 0.100 |
Why?
| | Clinical Enzyme Tests | 1 | 2013 | 9 | 0.100 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 594 | 0.100 |
Why?
| | Salicylates | 1 | 2013 | 29 | 0.100 |
Why?
| | Blood Cell Count | 1 | 2013 | 55 | 0.100 |
Why?
| | Deoxycholic Acid | 1 | 2013 | 14 | 0.100 |
Why?
| | Adolescent Behavior | 1 | 2018 | 498 | 0.100 |
Why?
| | Spasm | 1 | 2013 | 21 | 0.100 |
Why?
| | Receptor, Cannabinoid, CB1 | 1 | 2013 | 39 | 0.090 |
Why?
| | Urinalysis | 1 | 2013 | 83 | 0.090 |
Why?
| | Blood Chemical Analysis | 1 | 2013 | 109 | 0.090 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 342 | 0.090 |
Why?
| | Osmolar Concentration | 2 | 2022 | 168 | 0.090 |
Why?
| | Mycoses | 1 | 2013 | 88 | 0.090 |
Why?
| | Chromatography, Liquid | 2 | 2025 | 453 | 0.090 |
Why?
| | Logistic Models | 1 | 2017 | 2142 | 0.090 |
Why?
| | Drug Combinations | 1 | 2013 | 399 | 0.090 |
Why?
| | Respiratory Insufficiency | 1 | 2015 | 330 | 0.080 |
Why?
| | Cohort Studies | 1 | 2022 | 6099 | 0.080 |
Why?
| | Immunocompromised Host | 1 | 2013 | 202 | 0.080 |
Why?
| | Medical Audit | 1 | 2011 | 77 | 0.080 |
Why?
| | Hepatic Encephalopathy | 1 | 2011 | 25 | 0.080 |
Why?
| | International Normalized Ratio | 1 | 2011 | 56 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1518 | 0.080 |
Why?
| | Liver Function Tests | 1 | 2011 | 105 | 0.080 |
Why?
| | Alanine Transaminase | 1 | 2011 | 151 | 0.080 |
Why?
| | Kidney | 1 | 2018 | 1511 | 0.080 |
Why?
| | Limit of Detection | 2 | 2022 | 92 | 0.080 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 617 | 0.070 |
Why?
| | Age Factors | 1 | 2017 | 3372 | 0.070 |
Why?
| | Mass Screening | 1 | 2018 | 1375 | 0.070 |
Why?
| | Asthma | 1 | 2021 | 1805 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 789 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2013 | 467 | 0.070 |
Why?
| | Time Factors | 1 | 2020 | 7173 | 0.070 |
Why?
| | Survival Rate | 1 | 2013 | 2110 | 0.070 |
Why?
| | Mental Disorders | 1 | 2017 | 1188 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2013 | 1072 | 0.060 |
Why?
| | Primary Health Care | 1 | 2018 | 1760 | 0.060 |
Why?
| | Suicide | 1 | 2015 | 737 | 0.060 |
Why?
| | Pain | 1 | 2013 | 794 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 6164 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2013 | 732 | 0.060 |
Why?
| | Animals | 3 | 2020 | 38417 | 0.060 |
Why?
| | Anthropometry | 1 | 2026 | 206 | 0.060 |
Why?
| | Autopsy | 1 | 2025 | 96 | 0.060 |
Why?
| | Depression | 1 | 2015 | 1599 | 0.050 |
Why?
| | Emergency Medical Services | 1 | 2011 | 691 | 0.050 |
Why?
| | Digoxin | 1 | 2023 | 27 | 0.050 |
Why?
| | Endrin | 1 | 2023 | 13 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2024 | 572 | 0.050 |
Why?
| | Toxicokinetics | 1 | 2022 | 8 | 0.040 |
Why?
| | Benzodiazepines | 1 | 2023 | 169 | 0.040 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2023 | 252 | 0.040 |
Why?
| | Valproic Acid | 1 | 2022 | 49 | 0.040 |
Why?
| | Brompheniramine | 1 | 2021 | 2 | 0.040 |
Why?
| | Guaifenesin | 1 | 2021 | 2 | 0.040 |
Why?
| | Pseudoephedrine | 1 | 2021 | 2 | 0.040 |
Why?
| | Chlorpheniramine | 1 | 2021 | 5 | 0.040 |
Why?
| | Doxylamine | 1 | 2021 | 3 | 0.040 |
Why?
| | American Heart Association | 1 | 2023 | 363 | 0.040 |
Why?
| | Phenylephrine | 1 | 2021 | 74 | 0.040 |
Why?
| | Drug Labeling | 1 | 2021 | 37 | 0.040 |
Why?
| | Vasodilation | 1 | 2025 | 522 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2010 | 5478 | 0.040 |
Why?
| | Homicide | 1 | 2021 | 68 | 0.040 |
Why?
| | Crotalus | 1 | 2020 | 24 | 0.040 |
Why?
| | Crotalid Venoms | 1 | 2020 | 30 | 0.040 |
Why?
| | Artificial Intelligence | 1 | 2023 | 389 | 0.030 |
Why?
| | Health Care Costs | 1 | 2021 | 428 | 0.030 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 26 | 0.030 |
Why?
| | Models, Biological | 1 | 2024 | 1772 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 593 | 0.030 |
Why?
| | Safety | 1 | 2017 | 358 | 0.030 |
Why?
| | Deglutition | 1 | 2015 | 73 | 0.030 |
Why?
| | Registries | 1 | 2021 | 2434 | 0.020 |
Why?
| | Biomarkers | 1 | 2023 | 4354 | 0.020 |
Why?
|
|
Wang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|